The University of Houston System, a Hispanic-Serving Institution, was awarded a $1,101,840 federal Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420). The grant, awarded on January 1, 2024, supports a research project titled "INVESTIGATING NEBIVOLOL IN TRIPLE-NEGATIVE BREAST CANCER" to be completed by December 31, 2026. The project aims to develop new treatments and advance scientific understanding of military health issues, with a focus on cancer research. The grant funds basic, translational, and clinical research at the University of Houston to investigate the use of the drug nebivolol for treating triple-negative breast cancer, a challenging form of the disease that disproportionately affects military members and veterans.
Generated 8/13/24, 9:08 AM